OCCLUGEL SAS.

Thanks to know-how and inventor’s team, Occlugel has developed new degradable drug delivery system (DDDS) for loco-regional treatments. Local delivery of antibiotics, glaucoma treatment or pain killer is tunable from few days to few weeks. Occlugel's DDDS are easy to inject per or post-operatively and could offer safety for physicians, a benefit for patients in accordance with the requirements of health insurance. These innovative and disruptive DDDS allow a swift access to market with a high potential for differentiation. Over the years Occlugel has created and developed the first degradable microspheres for embolization and chemoembolization in the world and had transferred it successfully to an US industrial. Recently, an original technology of microspheres with X-rays and MRI visibility was transferred by Occlugel to a European pharmaceutical group. Occlugel owns a genuine expertise in process transferring of its technologies towards industry and is looking for long-standing relationships to develop its new DDDS.